India’s Hilleman Plans ‘Affordable’ Vaccine Against Group B Strep
Executive Summary
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
You may also be interested in...
Hilleman CEO Moving On, Hands Baton To Ex-Takeda Executive
Hilleman CEO Davinder Gill is leaving the global vaccine R&D organization after eight years at the helm and several mileposts. Incoming CEO Raman Rao takes charge from 1 February.
Hilleman’s Shigella Vaccine Moves To Trials In Europe, Africa In ‘Big Step Forward’
India’s Hilleman Laboratories’ pioneering vaccine to treat shigellosis, a form of dysentery that’s a leading killer of young children, is moving into clinical trials in Europe and Africa, but expected launch date has been pushed back in parallel.
Top US Court Lifts Discovery Stay On Price-Fixing
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.